Recruiting
Phase 4

PEG3350 vs. Senna

Sponsor:

St. Joseph's Health, New York

Code:

NCT06825260

Conditions

Obstructive Defecation Syndrome

Postoperative Constipation

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

Senna

Polyethylene glycol 3350

Study Details

Brief summary:

The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are:

What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery

Conditions

Obstructive Defecation Syndrome

Postoperative Constipation

Study ID

NCT06825260

Start date

Apr 23, 2025

Status verified date

Nov, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Inclusion criteria includes women scheduled for urogynecologic surgery for pelvic organ prolapse and/or stress urinary incontinence and at least 18 years old.

Exclusion Criteria:

  • Exclusion criteria include undergoing concomitant bowel surgery (colonic resection, anal sphincter repair, rectovaginal fistula repair, rectopexy) or placement of a sacral neuromodulation device alone.

Study Design

Enrollment

254 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Senna

Senna (Sennosides), oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days

active comparator: Polyethylene Glycol 3350

Polyethylene Glycol 3350, oral, 17g, daily for 7 days

Interventions

Senna

Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days

Polyethylene glycol 3350

Polyethylene Glycol 3350, oral, 17g, daily for 7 days

Primary outcome measure

  • Postoperative ODS in Patients Taking PEG3350 vs Senna [ Time Frame: From enrollment to the end of treatment at 7 days after surgery. ]

Central Contacts and Locations

Central contacts

Locations

St. Joseph's Health Hospital

Recruiting

Syracuse, New York, United States, 13203

Contacts

Principal Investigator:

Keila S Muniz, MD

More Information

Sponsor

St. Joseph's Health, New York

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • obstructive defecation syndrome (ODS)
  • Postoperative constipation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by St. Joseph's Health, New York on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.